HemaCure, Inc. is developing a next gen cell and gene therapy to treat neurodegenerative and rare diseases with an initial focus on Parkinson's. Much like in immuno-oncology, we aim to help the body cure itself. Based on IP from the Univ of Texas, and published proof-of-concept animal data in Parkinson's mice, we plan to use the seed funds to finish a first-in-human clinical trial package for a Series A from strategic and institutional investors.